Results 301 to 310 of about 87,925 (315)
Some of the next articles are maybe not open access.
Imatinib is receptive to a collaboration
Blood, 2011Before the introduction of imatinib, biologic therapy with IFN-α was the most promising treatment option for CML because it induced durable remissions in a subset of chronic-phase patients. 1 However, because of its toxicity as well as its limited and unpredictable efficacy, IFN-α therapy has been displaced by Bcr-Abl kinase inhibitors, which have ...
openaire +3 more sources
2017
Imatinib mesylate (Gleevec, Glivec, Novartis) is a selective inhibitor of ABL, ARG, KIT, PDGFR, and some oncogenic forms, most notably BCR-ABL. Accelerated approval was initially granted by the Food and Drug Administration (FDA) in 2001 for the treatment of Ph+CML after the failure of IFNα therapy. Approval was extended later that year to pediatric CML
openaire +2 more sources
Imatinib mesylate (Gleevec, Glivec, Novartis) is a selective inhibitor of ABL, ARG, KIT, PDGFR, and some oncogenic forms, most notably BCR-ABL. Accelerated approval was initially granted by the Food and Drug Administration (FDA) in 2001 for the treatment of Ph+CML after the failure of IFNα therapy. Approval was extended later that year to pediatric CML
openaire +2 more sources
New England Journal of Medicine, 2017
The initial successes of combination chemotherapy were stunning. Childhood acute leukemia, several forms of lymphoma, and testicular cancer all became largely curable malignant conditions. Adjuvant chemotherapy led to dramatically longer survival among persons with breast cancer.
openaire +3 more sources
The initial successes of combination chemotherapy were stunning. Childhood acute leukemia, several forms of lymphoma, and testicular cancer all became largely curable malignant conditions. Adjuvant chemotherapy led to dramatically longer survival among persons with breast cancer.
openaire +3 more sources